If you are wondering whether McKesson still looks attractive after its strong run, or whether much of the potential upside is ...

McKesson saw strong 2025 growth from GLP-1 tailwinds, but fading momentum, weak margins, and a 21x forward P/E show ...

Discover why McKesson (MCK) is a Buy: strong revenue, margin gains, and robust capital returns suggest 13.5% upside. Click here to read my most recent analysis.

McKesson Corporation (NYSE: MCK) will release its third quarter fiscal 2026 financial results after market close on Wednesday ...

McKesson (MCK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

Healthcare giant McKesson Corp. on Tuesday said it will spin off its Technology Solutions unit and merge it with revenue cycle company Change Healthcare, creating a yet-to-be named healthcare services ...

McKesson has entered into a definitive agreement to acquire CoverMyMeds, a developer of electronic prior authorization technology, for $1.1 billion or $0.9 billion net of cash incremental cash ...

IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) has released its fiscal 2025 third quarter financial results. Results can be accessed on McKesson’s ...

McKesson is one of the largest healthcare companies on earth. It is known as a $264 billion revenue distributor of pharmaceuticals and medical supplies, but its business has much more breadth. The ...

(Reuters) - A $141 million settlement between McKesson Corp and a class of shareholders accusing the drug distributor of hiding the fact that it profited from a price-fixing conspiracy among generic ...